Insights into the (GCT) Gene/Cell Therapy market & challenges facing market entrants and commercialization | Ascella Health

Continuing advances in cell and gene therapy (CGT) are transforming the pharmacy and point of care ecosystem. Recent launches of new CGTs have yielded mixed results on getting the right therapy to the right patients.  The CGTs pipeline and approvals are likely to rise dramatically in the near future. In 2024 alone, up to 21 cell therapy launches and as many as 31 gene therapy launches are on the horizon. Therefore, the launch readiness for these products should be effective so that the therapies can benefit as many patients as possible while ensuring a sufficient return on manufacturers’ investments. With so many new CGTs poised for commercialization, it’s imperative to consider innovative ways for a product launch that benefits CGTs patients. Ensuring that the market, the product, and the company itself are fully prepared for an effective launch will enable success.   Podcast Participants: Michelle Rice, CEO, Michelle Rice & Associates Kenneth Mankowski, DO, FACN, MS Neurologist Specialist, CNS & MS Institute Host:  Michael Baldzicki